| | | | | | Préparation | Taille des prés. | PEF | PP | QP | CQ | Composition | Titulaire de l'aut. | Cat. | | | | |
|---|
|
| | | IPro | | | Fentanyl-Piramal | 50 x 2 ml | DDP | DDP | N.O. | | Solution pour perfusion: Fentanylum | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G |  |
| | | IPro | | | Fentanyl-Piramal | 50 x 10 ml | DDP | DDP | N.O. | | Solution pour perfusion: Fentanylum | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IPro | | | Fentanyl Sintetica 0.02
mg/1 ml | 10 1 ampoule(s) à 1 ml | DDP | DDP | N.O. | | Solution injectable: Fentanylum 20 µg/ml | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Fentanyl Sintetica 0.05
mg/1 ml | 10 1 ampoule(s) à 2 ml | DDP | DDP | N.O. | | Solution injectable: Fentanylum 50 µg/ml | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Fentanyl Sintetica 0.05
mg/1 ml | 10 1 ampoule(s) à 10 ml | DDP | DDP | N.O. | | Solution injectable: Fentanylum 50 µg/ml | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Fentanyl-Mepha | 10 | DDP | DDP | N.O. | | Solution injectable: Fentanylum 50 µg/ml | Mepha Pharma AG | A+ | FB | | G | |
| | | IPro | | | Fentanyl-Mepha | 10 | DDP | DDP | N.O. | | Solution injectable: Fentanylum 50 µg/ml | Mepha Pharma AG | A+ | FB | | G | |
| | | | | | Fentanyl-B. Braun i.v. | 10 x 2 ml | DDP | DDP | N.O. | | Solution injectable: 2 Principes actifs | B. Braun Medical AG | A | FB | | G | |
| | | | | | Fentanyl-B. Braun i.v. | 10 x 5 ml | DDP | DDP | N.O. | | Solution injectable: 2 Principes actifs | B. Braun Medical AG | A | FB | | G | |
| | | | | | Fentanyl-B. Braun i.v. | 10 x 10 ml | DDP | DDP | N.O. | | Solution injectable: 2 Principes actifs | B. Braun Medical AG | A | FB | | G | |
|
| | | IPro | | Sp | Rapifen | 5 1 ampoule(s) à 2 ml | DDP | DDP | N.O. | | Solution pour perfusion: Alfentanilum | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IPro | | Sp | Rapifen | 50 1 ampoule(s) à 10 ml | DDP | DDP | N.O. | | Solution pour perfusion: Alfentanilum | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
|
| | | IPro | | Sp | Sufenta | 5 1 ampoule(s) à 2 ml | DDP | DDP | N.O. | | Solution injectable: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IPro | | Sp | Sufenta | 5 1 ampoule(s) à 10 ml | DDP | DDP | N.O. | | Solution injectable: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IPro | | Sp | Sufenta forte | 5 1 ampoule(s) à 1 ml | DDP | DDP | N.O. | | Solution injectable: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IPro | | Sp | Sufenta forte | 5 1 ampoule(s) à 5 ml | DDP | DDP | N.O. | | Solution injectable: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
|
| | | IPro | | Sp | Remifentanil Fresenius 1 mg | 5 Flacon perforable | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Remifentanilum 1 mg | Fresenius Kabi
(Schweiz) AG | A+ | FB | | G | |
| | | IPro | | Sp | Remifentanil Fresenius 2 mg | 5 Flacon perforable | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Remifentanilum 2 mg | Fresenius Kabi
(Schweiz) AG | A+ | FB | | G | |
| | | IPro | | Sp | Remifentanil Fresenius 5 mg | 5 Flacon perforable | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Remifentanilum 5 mg | Fresenius Kabi
(Schweiz) AG | A+ | FB | | G | |
| | | IPro | | Sp | Ultiva 1 mg | 5 Flacon perforable | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Remifentanilum 1 mg | Aspen Pharma Schweiz
GmbH | A+ | FB | | G | |
| | | IPro | | Sp | Ultiva 2 mg | 5 Flacon perforable | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Remifentanilum 2 mg | Aspen Pharma Schweiz
GmbH | A+ | FB | | G | |
| | | IPro | | Sp | Ultiva 5 mg | 5 Flacon perforable | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Remifentanilum 5 mg | Aspen Pharma Schweiz
GmbH | A+ | FB | | G | |
|
| | | IPro | | | Bupivacain 1mg/mL -
Fentanyl 2 µg/ml
Sintetica | Sachet(s) à 250 ml | DDP | DDP | N.O. | | soluzione per infusione: 2 Principes actifs | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Bupivacain 1mg/mL -
Fentanyl 2 µg/ml
Sintetica | 5 1 Sachet(s) à 250 ml | DDP | DDP | N.O. | | soluzione per infusione: 2 Principes actifs | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Bupivacain 1.25 mg/mL -
Fentanyl 2 µg/ml
Sintetica | Sachet(s) à 250 ml | DDP | DDP | N.O. | | soluzione per infusione: 2 Principes actifs | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Bupivacain 1.25 mg/mL -
Fentanyl 2 µg/ml
Sintetica | 5 1 Sachet(s) à 250 ml | DDP | DDP | N.O. | | soluzione per infusione: 2 Principes actifs | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Ropivacain 1 mg/ml -
Fentanyl 2 ug/ml
Sintetica | 10 x 100 ml | DDP | DDP | N.O. | | soluzione per infusione: 2 Principes actifs | Sintetica SA | A+ | FB | | G | |
| | | IPro | | | Ropivacain 2 mg/ml -
Fentanyl 2 ug/ml
Sintetica | 5 x 250 ml | DDP | DDP | N.O. | | soluzione per infusione: 2 Principes actifs | Sintetica SA | A+ | FB | | G | |
